Cancer Research Communications

SEP 4, 2026 · JOURNAL ARTICLE

A Phase 1 Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients With Advanced Gastrointestinal Cancers

Cancer Research Communications

First-in-human Phase 1 dose escalation with primary focus on safety and tolerability; anti-tumor activity is secondary and minimal (2.5% ORR), consistent with early-phase exploratory work.

AUG 11, 2026 · JOURNAL ARTICLE

Early EGFR inhibition triggers actionable tumour and microenvironmental remodelling in lung cancer

Cancer Research Communications

Single-arm neoadjuvant study with comprehensive molecular profiling showing early tumour and microenvironmental changes, but limited by small sample size, lack of control arm, and surrogate endpoints rather than hard clinical outcomes.

AUG 10, 2026 · JOURNAL ARTICLE

Ex vivo tumor derived organoid pharmacotyping identifies personalized therapeutic options for biliary tract cancer patients

Cancer Research Communications

Single-centre feasibility study of organoid drug testing in a small sample with uncontrolled clinical outcomes; demonstrates proof-of-concept but lacks comparison group and prospective validation.

AUG 10, 2026 · JOURNAL ARTICLE

Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses

Cancer Research Communications

A pilot clinical trial with critically limited enrollment (N=3) that confirms safety and feasibility but cannot establish efficacy; accompanied by mechanistic preclinical work in a mouse model.